[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carcinoma-of-unknown-primary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carcinoma-of-unknown-primary":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,68,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100286553","blood-tests-and-questionnaires-in-studying-adherence-to-preventative-swallowing-exercises-in-participants-with-metastatic-head-and-neck-cancer-100286553",false,"NCT03010150","Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer","Modeling Adherence to Preventive Swallowing Exercises in Head and Neck Cancer","Inclusion Criteria:\n\n* Are dispositioned to receive radiation with curative intent for nasopharyngeal, oropharyngeal, hypopharyngeal, laryngeal, or an unknown primary cancer with cervical metastases\n* Are stage II-IVb for non- human papillomavirus (HPV)- related oropharyngeal cancer\n* Have HPV- related oropharynx cancer that is T1, have nodal involvement with no distant metastasis or have HPV- related oropharynx cancer that is at least T2 with no distant metastasis\n* Are stage II-IVb for laryngeal cancer\n* Are stage I-IVb for hypopharyngeal\n* Are stage I-IVb for nasopharyngeal cancer\n* Have stage I-III unknown primary cancer with cervical\n\nExclusion Criteria:\n\n* Have other cancer diagnoses, except non-melanoma skin cancer\n* Had treatment for previous head and neck cancer or radiation to the head and neck\n* Have a history of previous head and neck surgery (excluding biopsy and\u002For tonsillectomy and\u002For tracheotomy)\n* Have a current oropharyngeal dysphagia unrelated to cancer diagnosis (e.g., dysphagia due to underlying neurogenic disorder)","ALL","18 Years",{"count":19,"type":20},471,"ESTIMATED","OBSERVATIONAL","This trial uses blood tests and questionnaires to study how well participants with head and neck cancer that has spread to other places in the body adhere to swallowing exercises to prevent future disease. Using blood tests to study cytokines (proteins related to the immune system) may help doctors learn if certain levels of cytokines affect whether or not side effects occur and if they put participants at risk for future disease. Questionnaires may help doctors learn about the reasons head and neck cancer participants may or may not follow the swallowing exercises that they are asked to perform after receiving radiation treatments.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54],"Carcinoma of Unknown Primary","Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Metastatic Head and Neck Carcinoma","Metastatic Malignant Neoplasm in the Uterine Cervix","Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Stage I Hypopharyngeal Carcinoma AJCC v8","Stage I Nasopharyngeal Carcinoma AJCC v8","Stage II Hypopharyngeal Carcinoma AJCC v8","Stage II Laryngeal Cancer AJCC v8","Stage II Nasopharyngeal Carcinoma AJCC v8","Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage III Hypopharyngeal Carcinoma AJCC v8","Stage III Laryngeal Cancer AJCC v8","Stage III Nasopharyngeal Carcinoma AJCC v8","Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IV Hypopharyngeal Carcinoma AJCC v8","Stage IV Laryngeal Cancer AJCC v8","Stage IV Nasopharyngeal Carcinoma AJCC v8","Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVA Hypopharyngeal Carcinoma AJCC v8","Stage IVA Laryngeal Cancer AJCC v8","Stage IVA Nasopharyngeal Carcinoma AJCC v8","Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVB Hypopharyngeal Carcinoma AJCC v8","Stage IVB Laryngeal Cancer AJCC v8","Stage IVB Nasopharyngeal Carcinoma AJCC v8","Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8","RECRUITING","2026-04-10",{"date":58,"type":59},"2026-04-15","ACTUAL",{"date":61,"type":59},"2016-12-29",{"date":63,"type":20},"2028-12-31",{"name":65,"class":66},"M.D. Anderson Cancer Center","OTHER",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100399013","cancer-genetic-testing-in-ethnic-populations-100399013","NCT04475640","Cancer Genetic Testing in Ethnic Populations","GEMINI - Cancer Genetic Testing in Ethnic Populations","Inclusion Criteria:\n\n* Patients at least 18 years of age\n* Individuals diagnosed with any solid tumor cancer including, but not limited to, gastrointestinal, breast, gynecological, genitourinary, skin, central nervous system (CNS)\u002Fbrain, head\u002Fneck, musculoskeletal or cancer of unknown primary; and presenting to Mayo Clinic (MC Arizona or MC Florida) for clinical management\u002Ftreatment; and patients receive genetic testing as described above\n* Self-identified as being from various ethnic populations including Hispanic\u002FLatino, Native American\u002FAlaskan, African American (including of African descent), Asian and other European populations\n* Blood collection is feasible (health, access and\u002For tolerability) for requested blood sample(s)\n* Individuals have agreed to participate and signed the study informed consent form\n\nExclusion Criteria:\n\n* Patients who have had prior germline genetic testing involving a 40+ gene panel within the last 24 months at Mayo Clinic and available for review by the research coordinator at time of consent\n* Past or current history of hematological cancer (including leukemias, multiple myeloma)\n* All bone marrow transplants",{"count":76,"type":20},1800,"INTERVENTIONAL",[79],"NA","This clinical trial examines the integration of cancer genetic testing in various ethnic populations. Studying individuals and families at risk of cancer may help identify cancer genes and other persons at risk. The information from this study may provide an opportunity for cancer risk stratification and individualized screening in these ethnic populations.",[82,24,83,84,85,86,87,88,89,90,91],"Breast Carcinoma","Central Nervous System Carcinoma","Digestive System Carcinoma","Genitourinary System Carcinoma","Head and Neck Carcinoma","Malignant Brain Neoplasm","Malignant Female Reproductive System Neoplasm","Malignant Musculoskeletal Neoplasm","Malignant Solid Neoplasm","Skin Carcinoma","2026-04-01",{"date":94,"type":59},"2026-04-02",{"date":96,"type":59},"2020-01-13",{"date":98,"type":20},"2028-10-15",{"name":100,"class":66},"Mayo Clinic",2,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":111,"conditions":112,"keywords":123,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":67},"100342582","genomic-investigation-of-unusual-responders-100342582","NCT03740503","Genomic Investigation of Unusual Responders","GENIUS","Inclusion Criteria:\n\n1. The patient must have either an exceptionally good or poor response to treatment, as indicated by their treating physician.\n\n   1. The exact definition of this is adaptable to the disease but a suggested guideline is a Complete Response, Partial Response or progression free interval of at least 6 months\n   2. Exceptionally poor response includes patients who were expected to respond favourably to a treatment but instead responded poorly (e.g dramatic tumor growth or death)\n2. The patient must have sufficient archival tumor available for sequencing.\n3. Deceased patients will also be considered for analysis (up to 30 patients per year) if they meet at least one of the following requirements:\n\n   a)) Patients who have archival tissue stored within the UHN Laboratory Medicine Program who have had a consent waiver granted by the REB to access the tissue.\n\n   b) Patients who have archival tissue banked for further research within the UHN Biospecimen Sciences Program\n\n   Exclusion Criteria:\n   * None",{"count":110,"type":20},100,"Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic agents in an effort to understand the fundamental genetic basis of this response. The present protocol seeks to retrospectively perform Exome, next-generation (DNA) sequencing and\u002For other molecular techniques on tumor samples to identify the genetic basis of a patient's exceptional response to chemotherapy.",[113,114,115,116,117,118,119,120,121,122,24],"Cancer","Breast Cancer","Non-small Cell Lung Cancer","Colorectal Cancer","Genitourinary Cancer","Gynecological Cancer","Upper Aerodigestive Tract Cancer","Pancreatobiliary Gastrointestinal Cancer","Melanoma (Skin)","Rare Cancer",[113,114,124,116,117,118,119,120,125,122,126],"Non- small Cell Lung Cancer","Melanoma Cancer","Unknown Primary Cancer","2025-01-30",{"date":129,"type":59},"2025-01-31",{"date":131,"type":59},"2013-11-01",{"date":133,"type":20},"2025-11",{"name":135,"class":66},"University Health Network, Toronto"]